Key terms
About CANF
Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CANF news
Apr 15
9:01pm ET
Can-Fite’s Namodenoson Shows Promise for Liver Cancer
Apr 15
7:05am ET
Can-Fite: Article by KOL presents Namodenoson to treat liver cancer, MASH
Apr 03
7:59am ET
Can-Fite Advances MASH Treatment into Phase IIb
Apr 03
7:09am ET
Can-Fite BioPharma submits IND to FDA for Phase IIb trial of namodenoson
Mar 29
2:00am ET
US Investors Beware: Tax Complications for Can-Fite BioPharma Shareholders
Mar 28
7:59am ET
Can-Fite BioPharma Reports Reduced Losses in 2023
Feb 28
7:31am ET
Can-Fite expands IP for NASH, gets patent allowance in Canada
Feb 07
9:35am ET
Buy Rating Affirmed for Can-Fite BioPharma Amidst Strategic Expansions and Positive Clinical Prospects
Jan 30
7:11am ET
Can-Fite BioPharma expands out licensing transaction with Ewopharma
CANF Financials
Key terms
Ad Feedback
CANF Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CANF Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range